Literature DB >> 1287681

Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics.

J J Legros1, C Gazzotti, T Carvelli, P Franchimont, M Timsit-Berthier, R von Frenckell, M Ansseau.   

Abstract

Apomorphine challenge tests (0.5 mg SC) were performed in 14 normal male volunteers and in 9 male schizophrenic inpatients, drug-free for at least 2 wk. In the normal volunteers, apomorphine induced an increase of serum growth hormone (GH) (maximum at 40 min), of vasopressin-neurophysin (hNpI) (maximum at 20 min), and oxytocin-neurophysin (hNpII) (maximum at 20 min). The release of neurophysins was independent of digestive side effects. In the schizophrenics, the GH level and release pattern were similar to those in the controls. The basal level of hNpI was reduced (t0: 0.42 +/- 0.1 ng/ml in the schizophrenics and 0.66 +/- 0.05 ng/ml in the controls, p < 0.02). In contrast, the basal level of hNpII was increased (3.34 +/- 0.04 ng/ml in the schizophrenics to 0.92 +/- 0.21 ng/ml in the controls, p = 0.001). The response to apomorphine was blunted, with no significant release of hNpI or of hNpII. Although the hNpII data are consistent with an increased dopaminergic tone, the psychopathological meaning of the increased basal oxytocinergic and decreased vasopressinergic functions remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287681     DOI: 10.1016/0306-4530(92)90019-4

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  18 in total

Review 1.  The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings.

Authors:  David M Cochran; Daniel Fallon; Michael Hill; Jean A Frazier
Journal:  Harv Rev Psychiatry       Date:  2013 Sep-Oct       Impact factor: 3.732

2.  Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

Authors:  Kai Macdonald; David Feifel
Journal:  Acta Neuropsychiatr       Date:  2011-12-19       Impact factor: 3.403

3.  Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders.

Authors:  Leah H Rubin; C Sue Carter; Jeffrey R Bishop; Hossein Pournajafi-Nazarloo; Lauren L Drogos; S Kristian Hill; Anthony C Ruocco; Sarah K Keedy; James L Reilly; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga; Elliot S Gershon; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-03-11       Impact factor: 9.306

Review 4.  Potential of Oxytocin in the Treatment of Schizophrenia.

Authors:  Paul D Shilling; David Feifel
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

5.  Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia.

Authors:  Andrew J Rosenfeld; Jeffrey A Lieberman; L Fredrik Jarskog
Journal:  Schizophr Bull       Date:  2010-03-22       Impact factor: 9.306

6.  Peripheral oxytocin is associated with reduced symptom severity in schizophrenia.

Authors:  Leah H Rubin; C Sue Carter; Lauren Drogos; Hossein Pournajafi-Nazarloo; John A Sweeney; Pauline M Maki
Journal:  Schizophr Res       Date:  2010-10-13       Impact factor: 4.939

7.  Endogenous oxytocin response to film scenes of attachment and loss is pronounced in schizophrenia.

Authors:  Lucas G Speck; Johanna Schöner; Felix Bermpohl; Andreas Heinz; Jürgen Gallinat; Tomislav Majic; Christiane Montag
Journal:  Soc Cogn Affect Neurosci       Date:  2019-01-04       Impact factor: 3.436

8.  Sex and diagnosis specific associations between DNA methylation of the oxytocin receptor gene with emotion processing and temporal-limbic and prefrontal brain volumes in psychotic disorders.

Authors:  Leah H Rubin; Jessica J Connelly; James L Reilly; C Sue Carter; Lauren L Drogos; Hossein Pournajafi-Nazarloo; Anthony C Ruocco; Sarah K Keedy; Ian Matthew; Neeraj Tandon; Godfrey D Pearlson; Brett A Clementz; Carol A Tamminga; Elliot S Gershon; Matcheri S Keshavan; Jeffrey R Bishop; John A Sweeney
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2015-11-09

9.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

10.  Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis.

Authors:  Leah H Rubin; C Sue Carter; Jeffrey R Bishop; Hossein Pournajafi-Nazarloo; Margret S H Harris; Scot K Hill; James L Reilly; John A Sweeney
Journal:  Schizophr Res       Date:  2013-03-07       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.